A Global, Long-Term, Prospective, Observational Registry of Patients With Anti-Aquaporin-4 Antibody-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated With Complement Component 5 Inhibitor Therapies (C5ITs) Eculizumab or Ravul

ConclusionsThese results show that patients with NMOSD place the highest value on reducing relapse risk and are more likely to select a ravulizumab-like profile than the others assessed.These findings can inform shared decision-making in selecting NMOSD treatments.Study Supported By: Alexion, AstraZeneca Rare Disease, funded this study and the medical writing and editorial support for this abstract (Apollo Medical Communications, part of Helios Global Group).Disclosure: Dr. Abbatemarco has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono.Dr. Abbatemarco has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon.Dr. Abbatemarco has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech.Dr. Abbatemarco has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics, Inc.The institution of Dr. Abbatemarco has received